CD8A and neoplasm: We observed that intratumoral injection of the OVV-mNbTIM3 significantly increased the composition of CD86+ and CD80+ in the DCs, gp70+, Granzyme B+ and IFN-γ+ in the CD8+ T cells indicating that OVV-mNbTIM3 treatment could effectively promote the maturation of DCs and the activation of tumor specific CD8+ T cells in the A20 model (Fig. 4A).